Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.

Our goal is to evaluate the safety and effectiveness of botulinum toxin type B (BTX - B) in superfunctional facial line management.

Twenty-four patients from academic teacher training received 400 to 800 units of BTX-B treatment in the occipital muscle, cricoid, or frontalis muscle. Patients were evaluated with wrinkle improvement score (WIS) and evaluated numerical kinetic line score (RNKLS) to determine side effects and pain. Evaluation took place at 1, 2, 4, 8 and 12 weeks.

The effect occurred within 72 hours. WIS and RNKLS were statistically good at all sites after treatment and the effect lasted 8 weeks. In general, patients acknowledged moderate improvement in WIS (grade 2) and 2 points improvement in RNKLS. Injection is more painful than BTX-A. No complications

BTX-B is a safe and effective technique for removing wrinkles. Further research is needed to clarify dose and duration

BTX - B is stable for a long time, is not ready for use, has BTX - A and anti - genetic properties.

One unit of MYOBLOC (botulinum toxin type b) corresponds to the calculated median lethal dose of intraperitoneal dose (LD 50) in mice. This assay was specifically performed for the production of MYOBLOC (botulinum toxin type B) by Solstice Neurosciences. Due to the details of various mouse LD50 assays (eg, vectors, dilution protocol, laboratory protocol), it is not possible to combine MYOBLOC's biologically active unit (botulinum toxin type B) with other botulinum toxins or other toxin units. Comparisons or transformations to units are assessed by other specific assays. Thus, the difference in species sensitivity to different botulinum neurotoxin serotypes eliminates dose-activity relationships in animals from human dose estimates. The specific activity of MYOBLOC (botulinum toxin type B) is in the range of 70 to 130 units / ng

MYOBLOC (botulinum toxin type b) is provided as a colorless transparent to pale yellow sterile injectable solution in a 5 mL glass vial. Each one-time preparation of the MYOBLOC vial contains 5,000 units of botulinum toxin type B, 0.05% human serum albumin, 0.01 M sodium succinate and 0.1 M sodium chloride, pH about 6. Unit MYOBLOC (b type meat) toxic toxin corresponds to the calculated median lethal dose of intraperitoneal dose (LD 50) in mice. This assay was specifically performed for the production of MYOBLOC (botulinum toxin type B) by Solstice Neurosciences. Due to the details of various mouse LD50 assays (eg, vectors, dilution protocol, laboratory protocol), it is not possible to combine MYOBLOC's biologically active unit (botulinum toxin type B) with other botulinum toxins or other toxin units. Compare or convert units using other specific measurement methods